{"id":405080,"date":"2025-08-18T00:04:32","date_gmt":"2025-08-17T22:04:32","guid":{"rendered":"https:\/\/medizinonline.com\/targeted-met-inhibition-after-progression-with-osimertinib\/"},"modified":"2025-07-14T17:34:21","modified_gmt":"2025-07-14T15:34:21","slug":"targeted-met-inhibition-after-progression-with-osimertinib","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/targeted-met-inhibition-after-progression-with-osimertinib\/","title":{"rendered":"Targeted MET inhibition after progression with osimertinib"},"content":{"rendered":"\n<p><strong>Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional agents to osimertinib after disease progression during first-line treatment with osimertinib. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Ftargeted-met-inhibition-after-progression-with-osimertinib%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Despite the success of osimertinib, a third-generation EGFR-TKI, in first-line therapy, the treatment of NSCLC after progression remains a challenge. SAVANNAH and ORCHARD have investigated the targeted addition of additional&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Ftargeted-met-inhibition-after-progression-with-osimertinib%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":405083,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Precision therapy","footnotes":""},"category":[11513,11370,11455,11548,11503],"tags":[84199,84184,11705,11706,84198,31032],"powerkit_post_featured":[],"class_list":["post-405080","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-oncology","category-pneumology","category-rx-en","category-studies","tag-egfr-tki-en","tag-elcc-2025-en","tag-lung-cancer-en","tag-nsclc-en","tag-precision-therapy","tag-recurrence","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-22 23:51:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":405075,"slug":"inhibition-ciblee-de-met-apres-progression-sous-osimertinib","post_title":"Inhibition cibl\u00e9e de MET apr\u00e8s progression sous osimertinib","href":"https:\/\/medizinonline.com\/fr\/inhibition-ciblee-de-met-apres-progression-sous-osimertinib\/"},"it_IT":{"locale":"it_IT","id":405043,"slug":"inibizione-mirata-di-met-dopo-progressione-con-osimertinib","post_title":"Inibizione mirata di MET dopo progressione con osimertinib","href":"https:\/\/medizinonline.com\/it\/inibizione-mirata-di-met-dopo-progressione-con-osimertinib\/"},"pt_PT":{"locale":"pt_PT","id":405037,"slug":"inibicao-especifica-da-met-apos-progressao-com-osimertinib","post_title":"Inibi\u00e7\u00e3o espec\u00edfica da MET ap\u00f3s progress\u00e3o com osimertinib","href":"https:\/\/medizinonline.com\/pt-pt\/inibicao-especifica-da-met-apos-progressao-com-osimertinib\/"},"es_ES":{"locale":"es_ES","id":404998,"slug":"inhibicion-dirigida-de-met-tras-progresion-con-osimertinib","post_title":"Inhibici\u00f3n dirigida de MET tras progresi\u00f3n con osimertinib","href":"https:\/\/medizinonline.com\/es\/inhibicion-dirigida-de-met-tras-progresion-con-osimertinib\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/405080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=405080"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/405080\/revisions"}],"predecessor-version":[{"id":405084,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/405080\/revisions\/405084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/405083"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=405080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=405080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=405080"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=405080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}